Navigation Links
HeartWare Reports Second Quarter 2012 Results

FRAMINGHAM, Mass. and SYDNEY, Aug. 7, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $29.1 million for the second quarter ended June 30, 2012.  This represents a 42 percent increase from $20.4 million in revenue for the same period of 2011.  Revenue from international markets increased to $24.9 million in the second quarter of 2012, from $14.1 million in the second quarter of 2011, a 76 percent increase.  Changes in foreign currency rates unfavorably impacted revenue by approximately $1.9 million in the second quarter of 2012, compared to the second quarter of 2011.

"During the second quarter, we generated global sales for the HeartWare® Ventricular Assist System of 318 units, up from 226 units in the second quarter of 2011.  International markets accounted for 276 units sold and approximately 86 percent of our 2012 second quarter revenue, reflecting strong support of our 100 customer sites in 26 countries," stated Doug Godshall, President and Chief Executive Officer.  "Following the positive recommendation of the Circulatory System Devices Advisory Committee in April, we have been focused on working with the FDA as it finalizes its review of our Premarket Approval (PMA) application for U.S. commercialization of the HeartWare Ventricular Assist System as a bridge to heart transplantation.

"In May, we announced the early completion of enrollment in our 450-patient ENDURANCE Destination Therapy study, resulting in an expected gap in U.S. clinical enrollment in the second quarter.  As we proceed through the two-year patient follow-up period for the trial, we have requested a Continued Access Protocol allocation for destination therapy from the FDA," added Mr. Godshall.  "Our second quarter results also reflect increased investment in our technology pipeline, particularly our MVAD® System for which human clinical testing is expected this year, as well as ramping of personnel in anticipation of expanded commercialization."

Total operating expenses for the second quarter of 2012 were $34.2 million, as compared to $20.2 million in the same period of 2011.  Research and development expense was $20.0 million for the second quarter of 2012, as compared to $10.3 million in the same period of 2011, primarily attributable to the Company's continuing clinical trial costs and research and development costs related to advancing HeartWare's pipeline technologies.  Selling, general and administrative expenses were $14.2 million in the second quarter of 2012, compared to $9.9 million in the second quarter of 2011.  The increase in selling, general and administrative expenses is related to a higher volume of commercial activity outside of the U.S. and an enhanced corporate infrastructure to support overall growth and anticipated commercialization in the U.S.

Net loss for the second quarter of 2012 was $22.8 million, or a $1.61 loss per basic and diluted share, compared to a $10.1 million net loss, or a loss of $0.73 per basic and diluted share, in the second quarter of 2011.  For the six months ended June 30, 2012, the Company recorded a net loss of $41.6 million, or a $2.94 loss per basic and diluted share, compared to a $19.5 million net loss, or a loss of $1.40 per basic and diluted share, in the first half of 2011.

At June 30, 2012, the Company had $131.0 million of cash, cash equivalents and investments, as compared to $144.5 million at March 31, 2012 and $163.2 million at December 31, 2011.

HeartWare will host a conference call on Tuesday, August 7, 2012 at 5:00 p.m. U.S. Eastern Daylight Time (being 7:00 a.m. Australian Eastern Standard Time, on August 8, 2012) to discuss the Company's financial results, highlights from the quarter and business outlook.  The call may be accessed by dialing 1-877-941-4775 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9761.

A live webcast of the call will also be available at the Company's website ( by selecting "HeartWare Second Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE®, HVAD®, MVAD® and HeartWare logos are registered trademarks of HeartWare, Inc.

Forward-Looking Statements
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of, and presentation of data related to, clinical trials, expected timing of regulatory filings and approvals, commercialization planning and research and development activities. Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility the FDA does not approve the marketing of the HeartWare® Ventricular Assist System in the U.S., and those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.  We may update our risk factors from time to time in Part II, Item 1A."Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Phone: +1 508 739 0864

- Tables to Follow-

 HEARTWARE INTERNATIONAL, INCCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2012201120122011Revenue, net

$   29,053$   20,389$
38,364Cost of revenue

12,6657,91323,49315,509Gross profit

16,38812,47631,90522,855Operating expenses:Selling, general and administrative

14,2049,89226,92018,556Research and development

20,00510,28040,01219,580Total operating expenses

34,20920,17266,93238,136Loss from operations

(17,821)(7,696)(35,027)(15,281)Other expense, net

(4,961)(2,400)(6,600)(4,246)Net loss

(22,782)$  (10,096)$  (41,627)$  (19,527)Net loss per common share — basic and diluted

(1.40)Weighted average shares outstanding — basic and diluted

14,15713,92314,13913,912HEARTWARE INTERNATIONAL, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited)June 30, 2012December 31, 2011ASSETSCurrent assets:Cash and cash equivalents

71,257Short-term investments, net

16,50191,925Accounts receivable, net

21,44314,953Inventories, net

34,67032,005Prepaid expenses and other current assets

6,0174,507Total current assets

193,132214,647Property, plant and equipment, net

19,21318,325Other assets, net

8,1937,760Total assets

240,732LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

5,025Other accrued liabilities

13,18512,436Total current liabilities

24,19317,461Convertible senior notes, net

97,20594,277Other long-term liabilities

2,9132,210Stockholders' equity

96,227126,784Total liabilities and stockholders' equity


SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Acquisition Of World Heart Corporation
2. HeartWare Schedules Second Quarter Conference Call And Webcast
3. HeartWare Names Peter F. McAree Chief Financial Officer
4. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
5. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
6. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
7. Heartware Schedules First Quarter Conference Call And Webcast
8. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Express Scripts Reports Second Quarter Results
11. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... nuevo enfoque combina la inmunoterapia con la terapia fotodinámica ... Clinical Cancer Research . --> Clinical ...
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Representative. As a franchise owner, Somu now offers travelers, value and care based ... packages, private cruise sales, as well as, cabin upgrades and special amenities such ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
Breaking Medicine News(10 mins):